Drawing for PF 72

USPTO serial 79233582

PF 72

Reviewed by CopyMark Law Group

Reg. 5736229Status 707Registered
Filing date
Status date
Registration date
Apr 30, 2019
Examiner
SEVERSON, JUSTIN
Law office
Historical data usage

What this means

This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.

Need help with PF 72?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

John P. McCormick

John P. McCormick Fish & Richardson P.C.P.O. Box 1022Minneapolis, MN 55440-1022United States

Goods and services

ClassDescriptionStatusFirst use
005Drug delivery agents [ consisting of compounds ] that facilitate delivery of a wide range of pharmaceuticals; [ drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; ] [ microspheres used as vehicles to deliver drugs in the nature of pharmaceutical preparations; ] [ pharmaceutical preparations and substances for use in drug delivery in cell and tissue; preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery formulations in the form of tablets, capsules, solutions, suspensions, or pellets with tamper resistant properties which facilitate or allow the delivery of a wide range of pharmaceuticals; peptides for drug delivery, namely, drug delivery agents consisting of peptides attached to drugs that facilitate delivery of pharmaceutical preparations; carriers for drug delivery, namely, drug delivery agent in the form of nanoparticle for transferring siRNA in the cell; drug delivery agents that facilitate the delivery of a wide range of pharmaceuticals; drug delivery agents in the form of dissolvable films and coatings for tablets that facilitate the delivery of pharmaceutical preparations; ] drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals [ ; drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of dissolvable films that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of dissolvable films that facilitate the delivery of nutritional supplements; drug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of coatings for tablets that facilitate the delivery of nutritional supplements; drug delivery agents consisting of compounds that facilitate delivery by inhalation of a wide range of pharmaceuticals ]ACTIVE—
010[ Drug delivery apparatus for medical purposes, namely, using microspheres for embolization; electromagnetic drug delivery apparatus for medical use; drug infusion pump; drug delivery devices; implantable drug delivery pump for use as drug delivery device sold empty; implantable medication infuser for use as drug delivery device sold empty; drug delivery platforms; implantable subcutaneous drug delivery devices sold empty; anaesthetic delivery apparatus; medical drug syringes; medical apparatus for introducing pharmaceutical preparations into the human body; medical apparatus for facilitating the inhalation of pharmaceutical preparations; surgical instruments and apparatus; medical products being medical syringes; implants consisting of artificial materials; orthopedic articles, namely, orthopedic walkers and orthopedic supports ]SECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 23, 2026INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Feb 23, 2026NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
Feb 23, 202671.PREGISTERED - PARTIAL SEC 71 ACCEPTED—
Feb 23, 2026APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Oct 30, 2025ES71TEAS SECTION 71 RECEIVED—
Apr 30, 2024REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Jun 30, 2020INNAINVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE—
Jun 16, 2020INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Mar 13, 2020FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Mar 6, 2020NREPNEW REPRESENTATIVE AT IB RECEIVED—
Feb 18, 2020FICSFINAL DISPOSITION NOTICE SENT TO IB—
Feb 18, 2020FIMPFINAL DISPOSITION PROCESSED—
Feb 18, 2020LIMNLIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED—
Oct 16, 2019COC.CORRECTION UNDER SECTION 7 - PROCESSED—
Oct 16, 2019PLGLASSIGNED TO PARALEGAL—
Sep 25, 2019LIMELIMITATION FROM THE IB EXAMINED AND ENTERED—
Jul 30, 2019FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
May 13, 2019CORNCORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED—
Apr 30, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Apr 12, 2019CRCVCORRECTION TRANSACTION RECEIVED FROM IB—
Apr 12, 2019LIMGLIMITATION OF GOODS RECEIVED FROM IB—
Apr 4, 2019LIMGLIMITATION OF GOODS RECEIVED FROM IB—
Feb 12, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 12, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 8, 2019GPNXNOTIFICATION PROCESSED BY IB—
Jan 23, 2019OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jan 23, 2019OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Jan 23, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Dec 26, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 22, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 21, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 21, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 7, 2018RFNTREFUSAL PROCESSED BY IB—
Jun 21, 2018RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jun 21, 2018RFRRREFUSAL PROCESSED BY MPU—
Jun 14, 2018RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jun 12, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 12, 2018MAFRAPPLICATION FILING RECEIPT MAILED—
Jun 8, 2018DOCKASSIGNED TO EXAMINER—
Jun 8, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 7, 2018REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance